These innovative compounds represent a significant progression in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose https://aprilugss626051.blogsuperapp.com/39690579/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide